Abbott reports improved detection rates for Oncodetect colorectal cancer test
New clinical data presented at ESMO shows Abbott’s Oncodetect whole-genome sequencing test improved detection sensitivity by 30 percentage points in colorectal cancer patients.
Abbott has released data from its Beta-CORRECT study, demonstrating that its Oncodetect whole-genome sequencing test achieved a 30-percentage-point absolute improvement in sensitivity for detecting colorectal cancer. These findings were presented at the European Society for Medical Oncology (ESMO) congress.
The study also underscored the clinical utility of molecular residual disease (MRD) testing in determining patient prognosis. Results indicated that patients testing positive for MRD faced a 10.6-fold higher risk of cancer recurrence, suggesting that the test could be a critical tool for identifying patients who require more aggressive treatment strategies.
This development is part of Abbott's broader effort to integrate advanced diagnostic tools into the cancer care continuum. By combining these findings with its existing presence in the colorectal cancer screening market—notably through the Cologuard test—the company aims to consolidate its diagnostic capabilities across the oncology sector.